|
|
|
| MRS-based efficacy assessment of brain metastasis treatment by GKS |
| GUO Qi, ZHANG Xue-ning, WU Meng-lin, SHI Dai, WEI Lu, XU De-sheng, ZHANG Yi-pei |
| The Second Hospital of Tianjin Medical University, Tianjin 300211, China |
|
|
|
|
Abstract Objective: To assess the efficacy of GKS and its clinical value during follow-up by detecting changes in MRS metabolite levels before and after brain metastasis treatment. Methods: 24 lesions of brain metastasis were treated with GKS, which were confirmed by clinical or pathology. MRI with contrast and MRS were performed within 24 hours to evaluate target lesions before GKS treatment, 1 month and 4 months after treatment. Tumor volumes were calculated, and metabolite contents were measured with post-processing software. Changes of metabolite contents in tumor parenchyma before and after GKS treatment were analyzed by ANOVA, and tumor volumes were compared by Kruskal-Wilcoxon and Wilcoxon rank sum test. Results: The changes of tumor volumes before GKS treatment, 1 month and 4 months after treatment were statistically significant (P＜0.05). There was no statistical significance before and 1 month after treatment, and only tumor volumes before and 4 months after treatment were statistically significant(P＜0.05). The changes of nCho, Cho/Cr, Cho/NAA and Cho/cNAA before GKS treatment, 1 month and 4 months after treatment were statistically significant(P＜0.05). Conclusions: MRS is able to show early responses of GKS treatment on brain metastasis and will evaluate GKS efficacy more accurately by combination with contrast MRI.
|
|
Received: 29 July 2014
|
|
|
|
|
|
|
|
|
2015, Vol. 26 
